Cynapsus Therapeutics Provides Company Update at Cowen & Co. 36th Annual Health Care Conference
March 07, 2016 06:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, March 07, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a...
Cynapsus Therapeutics to Present at Cowen & Co. 36th Annual Health Care Conference
March 01, 2016 08:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, March 01, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a...
Cynapsus Therapeutics to Present at Noble Financial Capital Markets Twelfth Annual Investor Conference
January 13, 2016 08:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Jan. 13, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) today announced its President and CEO, Anthony Giovinazzo, will present an overview of the Company's...
Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data Science Approaches in Phase 3 Parkinson’s Clinical Study
January 07, 2016 08:00 ET
|
Cynapsus Therapeutics Inc.
Pivotal Trial of Cynapsus’ Under-the-Tongue Apomorphine Formulation Will Include Technology-Enabled Sub-Study to Gather and Analyze Objective Patient Data on Disease Progression and Medication...
Cynapsus Therapeutics Completes Short-Form Amalgamation With Wholly-Owned Subsidiary
January 04, 2016 16:15 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus” or the “Company”) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (“CNS”) pharmaceutical company...
Cynapsus Therapeutics Announces Successful Completion of Bioavailability and Pharmacokinetic Study and Provides Update on European Clinical Plans
December 10, 2015 16:10 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system ("CNS") pharmaceutical company developing and preparing to...
Cynapsus Therapeutics Announces Positive Data Presentations at World Congress on Parkinson's Disease and Related Disorders Meeting
December 08, 2015 02:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Dec. 8, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. ("Cynapsus") (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system ("CNS") pharmaceutical company developing and preparing to...
Cynapsus Therapeutics Expands Senior Leadership Team
November 19, 2015 16:15 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty CNS pharmaceutical company developing and preparing to commercialize a fast-acting,...
Cynapsus Therapeutics to Present at Stifel 2015 Healthcare Conference
November 13, 2015 06:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) today announced it will present an overview of the company's Parkinson's disease program and outlook at...
Cynapsus Therapeutics Reports Third Quarter 2015 Financial Results and Recent Developments
November 12, 2015 06:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) ("Cynapsus" or the "Company"), a specialty central nervous system ("CNS") pharmaceutical company...